Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics Inc (NASDAQ: INDP) is a preclinical-stage biotech company pioneering novel immunotherapies that activate both innate and adaptive immune responses. This dedicated news hub provides investors and researchers with essential updates on the company’s innovative bacterial platform and clinical progress.
Access real-time announcements about INDP’s Decoy20 candidate, strategic collaborations, and preclinical findings across multiple cancer types. Our curated collection includes press releases on trial designs, partnership developments, and scientific presentations – all critical for understanding the company’s position in immuno-oncology.
Key updates cover three focus areas: 1) Pipeline advancements in colorectal/pancreatic cancers and lymphoma 2) Mechanism of action insights from TLR/STING pathway activation 3) Strategic initiatives enhancing combination therapy potential. Bookmark this page for unfiltered access to primary source materials that inform investment and research decisions.
Indaptus Therapeutics (Nasdaq: INDP) has announced the addition of Morristown Medical Center as a new clinical trial site for its Phase 1 trial of INDP-D101, a treatment for advanced solid tumors. Patient screening is expected to begin soon. The trial aims to assess the safety, tolerability, and pharmacokinetics of Decoy20, the company's lead compound. The expansion of trial sites is expected to expedite patient enrollment, aiding in gathering initial data. Indaptus believes Decoy20 has the potential to innovate solid tumor treatments, with ongoing studies showing promising pre-clinical results against various carcinomas.
Indaptus Therapeutics (Nasdaq: INDP) has initiated its first-in-human Phase 1 clinical trial, INDP-D101, evaluating Decoy20 for patients with advanced solid tumors. The trial commenced at USC Norris Cancer Center, aiming to assess safety, tolerability, and pharmacokinetics of Decoy20. The study will determine the maximum tolerated dose and investigate its clinical activity. Encouraged by preclinical data, Indaptus aims to advance to the trial's expansion phase following dose determination. Initial cohort results are expected in 2023.
Indaptus Therapeutics (Nasdaq: INDP) has reported its Q3 2022 financial results and is on track to initiate a Phase 1 clinical trial of Decoy20 for treating solid tumors in Q4 2022. The FDA cleared the IND application for this trial, aimed at evaluating Decoy20's safety and efficacy. In Q3 2022, R&D expenses rose to $1.6 million, while general and administrative expenses decreased to $2.0 million. The company holds approximately $28.5 million in cash and expects to fund operations into Q2 2024 without additional financing.
Indaptus Therapeutics announced that CEO Jeffrey A. Meckler will present at the LD Micro Main Event XV from October 25-27, 2022, at the Luxe Sunset Boulevard Hotel in Los Angeles. The presentation is scheduled for October 25 at 3:30 PM PT (Track 3). Interested parties can register to watch the presentation online. Indaptus focuses on immunotherapy, leveraging patented technology to activate immune responses against tumors and chronic viral infections. The company aims to develop innovative therapies and will hold one-on-one meetings during the conference.
Indaptus Therapeutics (Nasdaq: INDP) announced its CEO, Jeffrey A. Meckler, will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference on September 12, 2022, at 2:00 PM ET. The event will be held at the Lotte New York Palace Hotel from September 12 to 14. A live webcast will be available on the company’s website, with a replay accessible for 90 days after the event. Management will also hold one-on-one meetings post-conference. Details for registration and additional information can be found in the press release.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the JMP Securities Life Sciences Conference on June 16, 2022, at 2:30 p.m. ET in New York City. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 90 days post-event.
Indaptus specializes in immunotherapy, focusing on innovative solutions for cancer and viral infections. Their patented technology aims to activate immune responses through intravenous administration of non-pathogenic bacteria, showing promise in pre-clinical trials for various cancers and chronic viral infections.
Indaptus Therapeutics (Nasdaq: INDP) will present a corporate overview at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET, by CEO Jeffrey A. Meckler. A live webcast will be available on the company's investors section of its website, with a replay accessible for 90 days afterward.
Indaptus specializes in immunotherapy, leveraging patented technology involving non-pathogenic bacteria to activate immune cells for anti-tumor and anti-viral responses. The company has received FDA clearance for a Phase 1 trial of Decoy20 targeting advanced solid tumors.
Indaptus Therapeutics recently announced that the FDA has cleared its IND application for a Phase 1 clinical trial of Decoy20 in patients with advanced solid tumors. Scheduled to start in the second half of 2022, the trial aims to evaluate the safety and preliminary efficacy of Decoy20, which targets tumors resistant to current therapies. Decoy20's unique technology mobilizes both innate and adaptive immune responses without inducing significant side effects. The trial will utilize a dose escalation design, and the therapy could potentially treat various cancers, including pancreatic and colorectal carcinomas.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 8:30 AM ET. A live webcast will be available on the company's website and will be archived for 90 days.
Indaptus focuses on immunotherapy, utilizing patented technology that activates innate and adaptive immune cells to combat tumors and viral infections, demonstrating potential in preclinical models against chronic HBV and HIV.
Indaptus Therapeutics has submitted an Investigational New Drug (IND) application for Decoy20, aimed at treating solid tumors, with a Phase 1 clinical trial expected to start in 2022. The submission signifies a crucial step in the development of Decoy20, a dual Toll-like receptor (TLR) agonist that shows promise in activating immune responses against cancers. Financially, the company reported a loss per share of $0.41 for Q1 2022, along with increased R&D and administrative expenses, totaling $3.4 million. Cash reserves decreased to $36.2 million from $39.1 million in Q4 2021.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
